Menezes Carla, Rodrigues Bernardo, Magalhães Elza, Melo Ailton
Division of Neurology and Epidemiology, Federal University of Bahia, Salvador, BA, Brazil.
Arq Neuropsiquiatr. 2007 Sep;65(3A):596-8. doi: 10.1590/s0004-282x2007000400009.
Botulinum toxin type A (BT-A) has been described as an important strategy to various types of pain such as cervical dystonia, myofascial pain syndrome and headache. Although BT-A efficacy has not been proven in tension type headache, its use in migraine continues controversial. In this open trial, we evaluated the efficacy of BT-A in refractory migraine. BT-A was injected in patients diagnosed with migraine who had previously used three classes of prophylactic drugs by at least one year with no response. The most important improvement was observed within 30 days, but pain intensity and frequency of headache had been decreased until the end of three months of follow up. Side effects of BT-A were mild and self limited. We conclude that BT-A seems to be a safe and effective treatment to refractory migraine patients.
A型肉毒杆菌毒素（BT-A）已被视为治疗多种疼痛的重要策略，如颈部肌张力障碍、肌筋膜疼痛综合征和头痛。尽管BT-A在紧张型头痛中的疗效尚未得到证实，但其在偏头痛治疗中的应用仍存在争议。在这项开放性试验中，我们评估了BT-A对难治性偏头痛的疗效。BT-A被注射到诊断为偏头痛的患者体内，这些患者此前至少使用过三类预防性药物一年但无反应。最重要的改善在30天内观察到，但直到随访三个月结束时，头痛的疼痛强度和频率都有所降低。BT-A的副作用轻微且为自限性。我们得出结论，BT-A似乎是治疗难治性偏头痛患者的一种安全有效的方法。
